Latest News

Thursday, January 04, 2018

Oculis Raises $20.3 Million in a Series B Financing Round to Advance Breakthrough Treatments for Ophthalmic Diseases

Oculis announced it has successfully closed a Series B financing round of CHF 20 million ($20.3 million). The funds will be used to advance the clinical development of the company’s lead program…

Read the full story

Thursday, January 04, 2018

Alimera Sciences Receives Acceptance of Filing to Obtain Approval for Iluvien Uveitis Indication in Europe

Alimera Sciences announced that it received validation of a Type II variation for Iluvien submitted on December 12, 2017. The Type II variation was submitted through the Mutual Recognition Procedure w…

Read the full story

Thursday, January 04, 2018

Allergan Plans to Eliminate More Than 1,000 Jobs as Part of Restructuring Initiative

Allergan on Wednesday unveiled in a regulatory filing that it plans to cut its labor force by more than 1,000 positions as part of a cost-cutting initiative. The drugmaker noted that &q…

Read the full story

Thursday, January 04, 2018

Pixium Vision Receives FDA Approval to Begin Human Clinical Study of Its PRIMA Retinal Implant in the US

Pixium Vision announced that it has received approval from the FDA to begin the clinical feasibility study for PRIMA, Pixium Vision’s new-generation miniaturized wireless photovoltaic subretinal…

Read the full story

Thursday, January 04, 2018

TearLab Submits 510(k) for FDA Clearance of TearLab Discovery Platform

TearLab announced that it has submitted a 510(k) application to the FDA for the potential clearance of its TearLab Discovery Platform, the company's next-generation in-vitro diagnostic testing sys…

Read the full story

Wednesday, January 03, 2018

Spark Therapeutics' Luxturna Will Cost $850,000 for a One-Time Treatment

The first gene therapy in the U.S. now has a price tag: $850,000 for the one-time treatment, or, more specifically, $425,000 per eye for a retinal disorder. The price is for Spark Therapeutics' Lu…

Read the full story

Wednesday, January 03, 2018

Xiidra Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease

Shire announced that Xiidra (lifitegrast ophthalmic solution 5%), a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adults, has been approved …

Read the full story

Wednesday, January 03, 2018

Glaukos Submits IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass System

Glaukos announced that it has submitted an investigational device exemption (IDE) application to the FDA seeking authorization to study its iStent infinite Trabecular Micro-Bypass System. The iSten…

Read the full story

Wednesday, January 03, 2018

Glaukos Submits IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass System

Glaukos announced that it has submitted an investigational device exemption (IDE) application to the FDA seeking authorization to study its iStent infinite Trabecular Micro-Bypass System. The iSte…

Read the full story

Wednesday, January 03, 2018

Omeros Reaches Agreement with FDA on OMS721 Phase 3 Trial Protocol for IgA Nephropathy

Omeros announced that it has reached agreement with the FDA on Omeros’ protocol for its phase 3 clinical trial evaluating OMS721 in patients with IgA nephropathy (IgAN). Patient enrollment is ex…

Read the full story

Tuesday, January 02, 2018

Pershing Square, Valeant to Pay $290 Million to End Lawsuit

Activist investor Bill Ackman’s Pershing Square Holdings Ltd. and Valeant Pharmaceuticals International Inc. agreed to pay $290 million to settle investor claims that they engaged in insider tra…

Read the full story

Tuesday, January 02, 2018

New Drug Approvals Hit 21-Year High in 2017

U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light -- more than double the previous year -- while the figure also rose in the European Union, according to a …

Read the full story

Tuesday, January 02, 2018

CooperVision Introduces MyDay Toric Daily Disposable Contact Lenses in the U.S.

Combining the design features of Biofinity toric with the Smart Silicone chemistry of MyDay, CooperVision announced the introduction of MyDay toric daily disposable contact lenses in the United States…

Read the full story

Tuesday, January 02, 2018

Study: More Ophthalmologists Using EHRs, but Say Productivity Is Down

Use of electronic health records (EHRs) has more than doubled among US ophthalmologists in the last decade, yet most of these physicians perceive EHRs as decreasing their productivity and increasing o…

Read the full story

Tuesday, January 02, 2018

Keith D. Carter, MD, Begins Term as 2018 President of the American Academy of Ophthalmology

Keith D. Carter, MD, FACS, began his term as the 122nd president of the American Academy of Ophthalmology on January 1. Dr. Carter was elected by the Academy's community of ophthalmologists in rec…

Read the full story
Load More
 Stock Price  Change 
 ADVM $3.98  0.00% 
 Aerie Pharmaceuticals, Inc. $58.63  -0.30% 
 Akorn, Inc. $33.56  -0.01% 
 Alimera Sciences, Inc. $1.27  -1.17% 
 Allergan $176.05  -0.60% 
 Applied Genetic Technologies $4.23  -1.74% 
 Bayer $31.03  -2.79% 
 Can-Fite Biopharma $1.87  2.75% 
 Carl Zeiss Meditec $46.04  -11.98% 
 Clearside Biomedical $6.36  2.25% 
 Cooper Companies, Inc. $230.79  0.94% 
 Eleven Biotherapeutics $0.86  -1.21% 
 Escalon Medical Corp. $0.18  5.88% 
 Essilor International $107.65  -4.06% 
 Glaukos $28.28  -0.98% 
 Imprimis Pharmaceuticals, Inc. $1.85  1.65% 
 Inotek Pharmaceuticals $3.03  -5.31% 
 Johnson & Johnson $145.78  0.68% 
 Merck & Company, Inc. $58.67  1.85% 
 NicOx $8.88  -13.79% 
 NovaBay Pharmaceuticals, Inc. $3.70  2.78% 
 Novartis AG Common Stock $86.63  1.12% 
 Ocular Therapeutix $5.63  14.66% 
 Ophthotech Corporation $2.87  2.69% 
 Quantel $6.40  -16.99% 
 Regeneron $366.79  -0.40% 
 Roche $32.03  2.10% 
 Second Sight Medical Products $2.03  1.25% 
 Shire $147.51  -0.61% 
 Spark Therapeutics, Inc. $52.67  -2.59% 
 STAAR Surgical Company $16.10  -0.31% 
 TearLab Corporation $0.69  65.78% 
 Thrombogenics $3.45  -13.01% 
 Valeant Pharmaceuticals $23.82  0.04% 
 Xoma $33.77  1.50%